However, more primary large scale and well-designed studies are still required to evaluate the interaction of CCND1G870A polymorphism with brain tumor risk.
We histologically and molecularly reviewed our pediatric brain tumors for unrecognized AT/RTs and evaluated the role of cyclin D1, a potential molecular target of hSNF5/INI1.